From the Lab to Orbit: How Microgravity Can Speed Up Drug Discovery

For decades, space was viewed primarily as a setting for scientific exploration and technological advances. Today, however, it is also beginning to attract the interest of the pharmaceutical industry.

Researchers, universities, space agencies, and private companies are conducting experiments in microgravity to understand how proteins, cells, and pharmaceutical compounds behave under conditions different from those found on Earth. The goal is to identify opportunities that could accelerate drug discovery and expand our knowledge of various diseases.

This trend has gained even more momentum recently. In 2025, Varda Space Industries announced that it had raised US$1.487 billion to expand pharmaceutical research conducted in orbit, underscoring the industry’s growing interest in using microgravity as a tool for biomedical innovation.

Although most pharmaceutical research continues to take place in laboratories on Earth, the advances seen in recent years show that microgravity could become an important ally in the search for new treatments.

What is microgravity?

Microgravity is a condition in which the effects of gravity are significantly reduced, as is the case on space stations orbiting Earth.

In this environment, various physical and biological phenomena begin to occur differently than they do in conventional laboratories. As a result, scientists are able to observe cellular, molecular, and structural behaviors that would be difficult to reproduce on Earth.

For this reason, organizations such as NASA use the International Space Station (ISS) to conduct experiments in the fields of health, biology, and pharmaceutical development.

Why is the pharmaceutical industry looking to space?

Developing a new drug is a complex process that can take more than a decade and require investments in the billions.

To develop more effective therapies, researchers need to understand in detail how proteins are organized, how molecules interact, and what mechanisms are involved in certain diseases.

Therefore, microgravity offers a unique opportunity. However, recent research suggests that protein crystals grown in a space environment may have more uniform and organized structures, allowing for more precise analyses and facilitating the discovery of new therapeutic targets.

What does microgravity reveal that Earth cannot show us?

One of the most promising areas of space-based pharmaceutical research involves protein crystallization.

On Earth, gravity continuously influences the movement of fluids and particles during crystal growth. In microgravity, these effects are reduced, allowing for the formation of more homogeneous structures.

According to recent analyses of pharmaceutical development in microgravity, crystals grown in space can provide more detailed structural information, helping scientists better understand complex diseases and develop more targeted drugs.

In addition, researchers have been exploring applications related to:

• Cancer cells;
• Neurodegenerative diseases;
• Cellular aging;
• Tissue regeneration;
• Immune response;
• Three-dimensional cell cultures.

These approaches can help reduce trial-and-error stages during the early phases of drug development.

Private companies are driving this new frontier

The pharmaceutical use of microgravity is no longer dependent solely on government agencies.

In recent years, private companies have begun to invest directly in research conducted in orbit. One of the best-known examples is Varda Space Industries, which develops platforms for manufacturing and pharmaceutical research in space.

In 2025, the company announced a new round of investments totaling US$1.487 billion to accelerate its pharmaceutical development programs in microgravity. Among the projects already completed is the crystallization of the drug ritonavir in orbit, demonstrating that certain structures can be produced differently than those observed on Earth.

In addition to Varda, other initiatives have been investigating how microgravity can contribute to new pharmaceutical formulations and advanced manufacturing processes.

The challenges remain significant

Despite its potential, space-based pharmaceutical research still faces significant challenges.

Among them are:

• High mission costs;
• Limited transport capacity;
• Operational complexity;
• Limited time for experiments;
• Need for regulatory validation;
• Industrial scalability.

In addition, many discoveries made in microgravity have yet to demonstrate consistent clinical and commercial benefits to justify their widespread adoption.

For this reason, experts view microgravity as a tool that complements traditional research, rather than a replacement for Earth-based laboratories.

The Next Frontier in Pharmaceutical Innovation

Pharmaceutical innovation has always sought environments capable of revealing information that conventional laboratories cannot easily observe.

Today, microgravity is emerging as one such opportunity. Recent studies indicate that the space environment can contribute to research involving protein crystallization, cell modeling, and the development of new pharmaceutical formulations.

Although most medications are still developed on Earth, the advances seen in recent years show that space could become a strategic ally in understanding complex diseases and accelerating scientific discoveries.

More than just a technological curiosity, microgravity research represents a new frontier for the pharmaceutical industry and for the future of healthcare.